Literature DB >> 17084814

Evaluation of the ability of N-terminal fragment of lethal factor of Bacillus anthracis for delivery of Mycobacterium T cell antigen ESAT-6 into cytosol of antigen presenting cells to elicit effective cytotoxic T lymphocyte response.

Subhash Chandra1, Manpreet Kaur, Shuchi Midha, Rakesh Bhatnagar, Nirupama Banerjee-Bhatnagar.   

Abstract

We report the ability of N-terminal fragment of lethal factor of Bacillus anthracis to deliver genetically fused ESAT-6 (early secretory antigen target), a potent T cell antigen of Mycobacterium tuberculosis, into cytosol to elicit Cytotoxic T lymphocyte (CTL) response. In vitro Th1 cytokines data and CTL assay proved that efficient delivery of LFn.ESAT-6 occurs in cytosol, in the presence of protective antigen (PA), and leads to generation of effective CTL response. Since CTL response is essential for protection against intracellular pathogens and, it is well known that only single T cell epitope or single antigenic protein is not sufficient to elicit protective CTL response due to variation or polymorphism in MHC-I alleles among the individuals, we suggest that as a fusion protein LFn can be used to deliver multiepitopes of T cells or multiproteins which can generate effective CTLs against intracellular pathogens like M. tuberculosis. It can be used to enhance the protective efficacy of BCG vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17084814     DOI: 10.1016/j.bbrc.2006.10.099

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  Mycobacterium tuberculosis Induction of Heme Oxygenase-1 Expression Is Dependent on Oxidative Stress and Reflects Treatment Outcomes.

Authors:  Neesha Rockwood; Diego L Costa; Eduardo P Amaral; Elsa Du Bruyn; Andre Kubler; Leonardo Gil-Santana; Kiyoshi F Fukutani; Charles A Scanga; JoAnne L Flynn; Sharon H Jackson; Katalin A Wilkinson; William R Bishai; Alan Sher; Robert J Wilkinson; Bruno B Andrade
Journal:  Front Immunol       Date:  2017-05-12       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.